Literature DB >> 8942151

Nerve damage in leprosy: an epidemiological and clinical study of 396 patients in west Nepal--Part 1. Definitions, methods and frequencies.

W H Van Brakel1, I B Khawas.   

Abstract

A historic cohort study was performed to determine the prevalence and incidence rates of nerve function impairment (NFI) as demonstrated by sensory testing with a nylon monofilament and standard tests of motor function. The records of 396 new leprosy patients registering at Green Pastures Hospital, Pokhara, between January 1988 and January 1992 were analysed. The mean follow-up period was 21 months. In all, 36% (141/396) of patients had either sensory or motor function impairment at their initial examination. For each nerve the prevalence of sensory and motor impairment is reported separately. The posterior tibial nerve was the most frequently affected (sensory) nerve (21%). Sensory impairment of the ulnar nerve was found in 17% of the patients; 8.8% had sensory impairment of the median nerve. The overall incidence rate of motor function impairment was 7.5 (5.4-10) per 100 person years at risk (PYAR). Sensory impairment had a significantly higher rate of 13 (10-17)/100 PYAR (rate ratio (1.8 (1.2-2.7), p = 0.0076). Bl patients had a significantly higher incidence rate of nerve function impairment than BT patients (rate ratio 2.3 (1.4-3.7), p = 0.006). Altogether 152/396 (39%) of the patients required corticosteroid treatment for 'recent' or 'acquired' impairment, and 78 of the patients (20%) developed severe nerve function impairment during or after antileprosy treatment. Analysis of potential risk factors for nerve function impairment showed a significant association with the extent of clinical disease expressed as the number of body areas (out of 9) with primary or secondary signs of leprosy (rate ratio 5.0 (1.5-17), p = 0.0091). It was concluded that nerve function impairment is a serious problem, often occurring during or after multidrug therapy. The extent of clinical disease expressed as a count of body areas involved, or of skin or nerve lesions may identify patients who are at increased risk of nerve damage.

Entities:  

Mesh:

Year:  1994        PMID: 8942151     DOI: 10.5935/0305-7518.19940020

Source DB:  PubMed          Journal:  Lepr Rev        ISSN: 0305-7518            Impact factor:   0.537


  5 in total

1.  Tibialis posterior transfer by interosseous route for the correction of foot drop in leprosy.

Authors:  R K Shah
Journal:  Int Orthop       Date:  2009-01-10       Impact factor: 3.075

Review 2.  Understanding the type 1 reactional state for early diagnosis and treatment: a way to avoid disability in leprosy.

Authors:  José Augusto da Costa Nery; Fred Bernardes Filho; Juliana Quintanilha; Alice Miranda Machado; Soraya de Souza Chantre Oliveira; Anna Maria Sales
Journal:  An Bras Dermatol       Date:  2013 Sep-Oct       Impact factor: 1.896

3.  Evaluation of altered patterns of tactile sensation in the diagnosis and monitoring of leprosy using the Semmes-Weinstein monofilaments.

Authors:  Marco Andrey Cipriani Frade; Fred Bernardes Filho; Claudia Maria Lincoln Silva; Glauber Voltan; Filipe Rocha Lima; Thania Loyola Cordeiro Abi-Rached; Natália Aparecida de Paula
Journal:  PLoS One       Date:  2022-08-10       Impact factor: 3.752

4.  Progression of leprosy disability after discharge: is multidrug therapy enough?

Authors:  Anna Maria Sales; Dayse Pereira Campos; Mariana Andrea Hacker; José Augusto da Costa Nery; Nádia Cristina Düppre; Emanuel Rangel; Euzenir Nunes Sarno; Maria Lucia Fernandes Penna
Journal:  Trop Med Int Health       Date:  2013-09       Impact factor: 2.622

5.  A Randomized Controlled Double Blind Trial of Ciclosporin versus Prednisolone in the Management of Leprosy Patients with New Type 1 Reaction, in Ethiopia.

Authors:  Saba M Lambert; Digafe T Alembo; Shimelis D Nigusse; Lawrence K Yamuah; Stephen L Walker; Diana N J Lockwood
Journal:  PLoS Negl Trop Dis       Date:  2016-04-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.